Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
dc.contributor.author | Hammerschlag, M R | |
dc.contributor.author | Roblin, P M | |
dc.date.accessioned | 2023-06-30T17:10:06Z | |
dc.date.available | 2023-06-30T17:10:06Z | |
dc.date.issued | 2000-05 | |
dc.identifier.citation | Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000 May;44(5):1409. doi: 10.1128/AAC.44.5.1409-1409.2000. PMID: 10819727; PMCID: PMC89886. | en_US |
dc.identifier.issn | 0066-4804 | |
dc.identifier.pmid | 10819727 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/10352 | |
dc.language.iso | en | en_US |
dc.relation.url | https://journals.asm.org/doi/epub/10.1128/aac.44.5.1409-1409.2000 | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | Antimicrobial agents and chemotherapy | en_US |
dc.source.volume | 44 | |
dc.source.issue | 5 | |
dc.source.beginpage | 1409 | |
dc.source.endpage | ||
dc.source.country | United States | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-06-30T17:10:07Z | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Pediatrics | en_US |
dc.description.degreelevel | N/A | en_US |
dc.identifier.journal | Antimicrobial agents and chemotherapy | |
dc.identifier.issue | 5 | en_US |